Clinical Trial Update: Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating once-daily arformoterol versus twice-daily dosing for efficacy and safety in chronic obstructive pulmonary disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• arformoterol (arformoterol)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 4 | Status: COMPLETED | Results posted: 2009-07-02